



GAU-1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

p#6

In Re the Application of:)

IRVIN)

Serial No.: 09/945,250 ✓)

Filed: August 31, 2001)

Atty. File No.: 2879-84)

For: "METHOD FOR TREATMENT OF
INFLAMMATORY DISEASE")INFORMATION DISCLOSURE
STATEMENT

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, DC 20231 ON 8/21/02
SHERIDAN ROSS P.C.

BY: Stephen Sumell

Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to Applicant's duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicant hereby provides a copy of each of the documents identified on the enclosed PTO Form 1449, although Applicant does not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicant that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

RECEIVED

AUG 28 2002

TECH CENTER 1600/2900

By: Angela Dallas

Angela K. Dallas
Registration No. 42,460
1560 Broadway, Suite 1200
Denver, CO 80202-5141
(303) 863-9700

Date: August 21, 2002

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2879-84SERIAL NO.
09/945,250O I P E INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT
IRVINFILING DATE
August 31, 2001

GROUP ART

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROP. |
|----------------------|---|--------------------|----------|------------------|-------|--------------|---------------------------|
| | 1 | 4,806,523 | 2/21/89 | Bentz et al. | 514 | 2 | |
| | 2 | 4,971,952 | 11/20/90 | Bentz et al. | 514 | 12 | |
| | 3 | 5,147,854 | 9/15/92 | Newman | 514 | 12 | |
| | 4 | 5,300,292 | 4/5/94 | Ulich | 424 | 85.2 | |
| | 5 | 5,376,368 | 12/27/94 | Ulich | 424 | 85.2 | |
| | 6 | 5,387,576 | 2/7/95 | Mitrani | 514 | 2 | |
| | 7 | 5,583,103 | 12/10/96 | Ruoslahti et al. | 514 | 8 | |
| | 8 | 5,595,722 | 1/21/97 | Grainger et al. | 424 | 9.2 | |
| | 9 | 5,674,483 | 10/7/97 | Tu et al. | 424 | 85.2 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB CLASS | TRANSLATION | |
|--|--|--------------------|------|---------|-------|--------------|-------------|----|
| | | | | | | | YES | NO |
| | | | | | | | | |

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

| | | |
|--|----|--|
| | 10 | Anderson, <i>Nature</i> , 392(supp):25-30 (1998) ✓ |
| | 11 | Atsuta et al., <i>Int. Arch. Allergy Immunol.</i> , 108:31-35 (1995) ✓ |
| | 12 | Aubert et al., <i>Thorax</i> , 49:225-232 (1994) |
| | 13 | Black et al., <i>Am. J. Physiol.</i> , 271:L910-L917 (1996) ✓ |
| | 14 | Branch, <i>TIBS</i> , 23:45-50 (1998) ✓ |
| | 15 | Broekelmann et al., <i>Proc. Natl. Acad. Sci. USA</i> , 88:6642-6 (1991) ✓ |
| | 16 | Crooke, <i>Antisense Research and Application</i> "Basic Principles of Antisense Therapeutics, Ch. 1, pp.1-50 (1998) ✓ |
| | 17 | Deguchi, <i>Ann. Rheum. Dis.</i> , 51:362-365 (1992) ✓ |
| | 18 | Denis, <i>Immunology</i> , 82:584-590 (1994) ✓ |
| | 19 | Flanagan et al., <i>Nature Biotechnology</i> , 17:48-52 (1999) ✓ |
| | 20 | Gauldie et al., <i>Ann. N.Y. Acad. Sci.</i> , 796:235-244 (1996) ✓ |
| | 21 | Giri et al., <i>Thorax</i> , 48:959-966 (1993) ✓ |
| | 22 | Goldman, <i>DDT</i> , 2(9):357-358 (1997) ✓ |
| | 23 | Gura, <i>Science</i> , 278:1041-1042 (1997) ✓ |

RECEIVED

AUG 28 2002

TECH CENTER 1600/2900

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
2879-84SERIAL NO.
09/945,250INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT
IRVINFILING DATE
August 31, 2001

GROUP ART



| | |
|----|--|
| 24 | Jachimczak et al., <i>Int. J. Cancer</i> , 65 :332-337 (1996) ✓ |
| 25 | Khalil, et al., <i>Am. J. Physiol.</i> 267 (<i>Lung Cell. Mol. Physiol.</i> 11):L498-L507 (1994) / |
| 26 | Khalil et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , 14 :131-138 (1996) / |
| 27 | Lawrence, <i>Eur. Cytokine Netw.</i> , 7 :363-374 (1996) ✓ |
| 28 | Lloyd, <i>DDT</i> , 2 (10):397-398 (1997) |
| 29 | Martinet et al., <i>Arch. Toxicol. Suppl.</i> , 18 :127-139 (1996) / |
| 30 | Ohno et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , 15 :404-409 (1996) / |
| 31 | Romberger et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , 7 :149-155 (1992) ✓ |
| 32 | Stein, <i>Nature Biotechnology</i> , 17 :751-752 (1999) |
| 33 | Uhl et al., <i>Am. J. Respir. Crit. Care Med.</i> , 154 :1834-1842 (1996) ✓ |
| 34 | Vignola et al., <i>Clin. Exp. Immunol.</i> , 106 :114-119 (1996) / |
| 35 | Wahl, et al., <i>J. Exp. Med.</i> , 177 :225-230 (1993) ✓ |
| 36 | Wangoo et al., <i>J. Clin. Pathol.</i> , 48 :339-345 (1995) / |
| 37 | Wess, <i>DDT</i> , 1 (12):529-532 (1996) ✓ |

RECEIVED
AUG 28 2002
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.